Skip to main content

Table 1 Clinical and Treatment Characteristics of Eight Patients with Preexisting Cardiomyopathy Undergoing Anthracycline Chemotherapy for Any Cancer, With or Without the Cardioprotectant, Dexrazoxane

From: Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series

Patient #. sex; age, years Cancer, Stage Chemotherapy regimen; anthracycline, cumulative dose, mg/m2 Cardiac history Before the start of anthracycline chemotherapy LVEF, %, by time since anthracycline therapy
ACEi Beta Blocker Aldosterone Antagonist Pre During Post 6 months post
Without dexrazoxane (controls)
 1. M; 87 PTCL, IV CHOP Doxorubicin, 300 NICM Yes Yes Yes 45 10
 2. M; 66 DLBCL, IV R-EPOCH Doxorubicin, 120 Ischemic Cardiomyopathy Yes Yes No 40 15
 3. M; 65 AML, M4 Cytarabine + Daunorubicin Daunorubicin, 540 Chemotherapy- related cardiomyopathy Yes No Yes 55 45 30 30
With dexrazoxane
 4. F; 67a HL, IIIB ABVD Doxorubicin, 300 NICM Yes Yes No 35 35 35 25
 5. F; 75 DLBCL, IIISE CHOP Doxorubicin, 300 NICM Yes Yes Yes 35 35 35 30
 6. F 70 Ovarian, IV Doxorubicin, 280 NICM No Yes No 45 40 40 40
 7. M; 73 NHL, IV ABVD Doxorubicin, 300 Ischemic cardiomyopathy Yes Yes Yes 40 40 40 40
 8. F; 68 Breast, IV Doxorubicin Doxorubicin, 300 NICM Yes Yes No 40 40 40 35
  1. LVEF left ventricular ejection fraction, ACEi angiotensin-converting enzyme inhibitors, DEX dexrazoxane, PTCL peripheral T-cell lymphoma, CHOP cyclophosphamide, doxorubicin, vincristine, and prednisone, NICM non-ischemic cardiomyopathy, DLBCL diffuse large B-cell lymphoma, M4 acute myelomonocytic leukemia, R-EPOCH rituximab, etoposide phosphate, prednisone, vincristine sulfate (Oncovin), cyclophosphamide, and doxorubicin hydrochloride (hydroxydaunorubicin), AML acute myeloid leukemia, ABVD Adriamycin (doxorubicin), Bleomycin, Vinblastine, Dacarbazine, HL Hodgkin lymphoma
  2. aPatient had a defibrillator before chemotherapy